ID Connect’s clinical consultant Erin McCreary, PharmD, BCPS, BCIDP, commented on the demise of Evusheld in Time Magazine’s Feb. 8, 2023, online edition. The article, titled “Without Evusheld, Immunocompromised People Are on Their Own Against COVID-19,” explores the effects of the end of the pandemic emergency declarations in May 2023 and the FDA’s revoked emergency-use authorization of Evusheld, a therapy first authorized in Dec. 2021.
You might also like…
Infectious Disease Connect Expands Telemedicine Services
Podcast – Navigating Infectious Disease with Dr. Rima Abdel Massih
Journal Article – Things We Do for No Reason – Ordering Streptococcus pneumoniae Urinary Antigen in Patients with Community-Acquired Pneumonia